{"session_id": 68, "bill_id": 24281, "bill_type": "House Bill", "bill_number": 1236, "bill_title": "regulate tetrahydrocannabinol for medical use.", "sponsors": [{"legislator_profile_id": 4403, "is_prime": true}], "keywords": ["Industrial Hemp", "Medical Cannabis", "Promulgation of Rules"], "audio": [{"meeting_datetime": "2023-02-08T07:45:00-06:00", "committee": "HST", "url": "https://sdpb.sd.gov/sdpbpodcast/2023/hst20.mp3", "start_seconds": 8487.0}, {"meeting_datetime": "2023-02-08T07:45:00-06:00", "committee": "HST", "url": "https://sdpb.sd.gov/sdpbpodcast/2023/hst20.mp3", "start_seconds": 8487.0}, {"meeting_datetime": "2023-02-08T07:45:00-06:00", "committee": "HST", "url": "https://sdpb.sd.gov/sdpbpodcast/2023/hst20.mp3", "start_seconds": 8487.0}], "bill_versions": [{"bill_id": 24281, "bill_version_id": 248093, "bill_version": "Introduced", "bill_version_date": "2023-02-01T11:33:46.29-06:00", "bill_text": "An Act to regulate tetrahydrocannabinol for medical use. Be it enacted by the Legislature of the State of South Dakota: Section 1. That \u00a7 38-35-1 be AMENDED: 38-35-1. Terms used in this chapter mean: (1) \"Applicant,\" a person, including the state or any agency or institution thereof, any municipality, political subdivision, public or private corporation, individual, partnership, limited liability company, association, or trust; and includes any officer or governing or managing body of any municipality, political subdivision, or public or private corporation, or limited liability company, applying for an industrial hemp grower license, processor license, or both; (2) \"Department,\" the Department of Agriculture and Natural Resources; (3) \"Greenhouse,\" any indoor structure or enclosed building capable of continuous cultivation throughout the year, no less than two thousand eight hundred and eighty square feet, not part of a residential dwelling. Greenhouses may contain multiple lots that are separated and identified; (4) \"Hemp\" or \"industrial hemp,\" the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a total delta-9 tetrahydrocannabinol concentration of not more than three-tenths of one percent on a dry weight basis; (5) \"Key participant,\" a sole proprietor, a partner in a partnership, a principal executive officer for a government entity, or a person with executive managerial control in a corporation or limited liability company; (6) \"Industrial hemp product,\" a finished manufactured product, or consumer product made from industrial hemp with a total delta-9 tetrahydrocannabinol concentration of not more than three-tenths of one percent, derived from or made by processing industrial hemp; (7) \"Lot,\" a contiguous area in a field or greenhouse containing the same variety or strain of hemp throughout the area; (8) \"Measurement of uncertainty,\" the parameter associated with the result of a measurement, that characterizes the dispersion of the values that could reasonably be attributed to the particular quantity subject to measurement; (9) \"Process\" or \"processing,\" to render raw industrial hemp plants or plant parts from their natural or original state to an initial processed form. Typical processing includes decortication, devitalization, crushing, or extraction; (10) \"Processor,\" a person that converts raw hemp into an initial processed form; (11) \"Produce\" or \"producing,\" to grow, germinate, dry, sort, grade, bale, grind, mill, pelletize, and harvest hemp plants in the field or in a greenhouse; (12) \"Product in process,\" the product being processed by a state licensed hemp processor or the transfer of that product at no higher than one percent total delta-9 tetrahydrocannabinol between one or more licensed hemp processors during the process of processing state or federally approved, lab-tested biomass from a licensed grower into a finished industrial hemp product; (13) \"Remediation,\" the process of rendering non-compliant cannabis compliant using methods accepted by the USDA; (14) \"Secretary,\" the secretary of the Department of Agriculture and Natural Resources; (15) \u201cTetrahydrocannabinol\u201d, the psychoactive substance contained in the plant of the genus cannabis or plant Cannabis sativa L., as well as the synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of the plant, or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, including delta-8, delta-9, and delta-10 tetrahydrocannabinol, and any compounds of these structures regardless of atomic positions; (15)(16) \"Total delta-9 THC or total delta-9 tetrahydrocannabinol,\" the value determined after the process of decarboxylation, or the application of a conversion factor if the testing methodology does not include decarboxylation, that expresses the potential total delta-9 tetrahydrocannabinol content derived from the sum of the THC and THCA content and reported on a dry weight basis; and (16)(17) \"Transporter,\" any person transporting, hauling, or delivering immature or mature hemp or product in process, but not industrial hemp product or sterilized seeds that are incapable of beginning germination. Section 2. That \u00a7 38-35-23 be AMENDED: 38-35-23. No industrial hemp may be grown, stored, or transported concurrently with marijuana, except by a medical cannabis establishment that is registered with the Department of Health pursuant to \u00a7 34-20G-55. A violation of this section is a Class 2 misdemeanor. Section 3. That chapter 38-35 be amended with a NEW SECTION: A licensee under this chapter must also register as a medical cannabis establishment with the Department of Health, pursuant to \u00a7 34-20G-55, in order to: (1) Engage in the isomerization of cannabinoids to create isomers of tetrahydrocannabinol, including delta-8, delta-9, and delta-10 tetrahydrocannabinol; and (2) Sell, distribute, or transport hemp or hemp products that were created using the isomerization of cannabinoids to create isomers of tetrahydrocannabinol, including delta-8, delta-9, and delta-10 tetrahydrocannabinol. A violation of this section is a Class 1 misdemeanor. Section 4. That \u00a7 34-20G-72 be AMENDED: 34-20G-72. The department shall promulgate rules pursuant to chapter 1-26: (1) Governing the manner in which the department shall consider petitions from the public to add a debilitating medical condition or treatment to the list of debilitating medical conditions as defined by this chapter, including public notice of and an opportunity to comment in public hearings on the petitions; (2) Establishing the form and content of registration and renewal applications submitted under this chapter; (3) Establishing a system to numerically score competing medical cannabis establishment applicants, in cases where more applicants apply than are allowed by the local government, that includes analysis of: (a) The preference of the local government; (b) In the case of dispensaries, the suitability of the proposed location and its accessibility for patients; (c) The character, veracity, background, qualifications, and relevant experience of principal officers and board members; and (d) The business plan proposed by the applicant, that in the case of a cultivation facility or dispensary shall include the ability to maintain an adequate supply of cannabis, plans to ensure safety and security of patrons and the community, procedures to be used to prevent diversion, and any plan for making cannabis available to low-income registered qualifying patients; (4) Governing the manner in which the department shall consider applications for and renewals of registry identification cards, that may include creating a standardized written certification form; (5) Governing medical cannabis establishments to ensure the health and safety of qualifying patients and prevent diversion and theft without imposing an undue burden or compromising the confidentiality of a cardholder, including: (a) Oversight requirements; (b) Record-keeping requirements; (c) Security requirements, including lighting, physical security, and alarm requirements; (d) Health and safety regulations, including restrictions on the use of pesticides that are injurious to human health; (e) Standards for the manufacture of cannabis products and both the indoor and outdoor cultivation of cannabis by a cultivation facility; (f) Requirements for the transportation and storage of cannabis by a medical cannabis establishment; (g) Employment and training requirements, including requiring that each medical cannabis establishment create an identification badge for each agent; (h) Standards for the safe manufacture of cannabis products, including extracts and concentrates; (i) Restrictions on the advertising, signage, and display of medical cannabis, provided that the restrictions may not prevent appropriate signs on the property of a dispensary, listings in business directories including phone books, listings in marijuana-related or medical publications, or the sponsorship of health or not-for-profit charity or advocacy events; (j) Requirements and procedures for the safe and accurate packaging, labeling, distribution, and tracking of medical cannabis; (k) Certification standards for testing facilities, including requirements for equipment and qualifications for personnel; and (l) Requirements for samples of cannabis and cannabis products submitted to testing facilities, including batch sizes to not exceed fifty pounds of cannabis intended for retail sale, batch sizes for homogenous cannabis products intended for retail sale, and procedures to ensure representative sampling; (6) Establishing procedures for suspending or terminating the registration certificates or registry identification cards of cardholders and medical cannabis establishments that commit multiple or serious violations of this chapter; (7) Establishing labeling requirements for cannabis and cannabis products, including requiring cannabis product labels to include the following: (a) The length of time it typically takes for a product to take effect; (b) Disclosing ingredients and possible allergens; (c) A nutritional fact panel; and (d) Requiring that edible cannabis products be clearly identifiable, when practicable, with a standard symbol indicating that it contains cannabis; (8) Establishing procedures for the registration of nonresident cardholders and the cardholder's designation of no more than two dispensaries, which shall require the submission of: (a) A practitioner's statement confirming that the patient has a debilitating medical condition; and (b) Documentation demonstrating that the nonresident cardholder is allowed to possess cannabis or cannabis preparations in the jurisdiction where the nonresident cardholder resides; (9) Establishing the amount of cannabis products, including the amount of concentrated cannabis, each cardholder and nonresident cardholder may possess; and (10) Establishing reasonable application and renewal fees for registry identification cards and registration certificates, according to the following: (a) Application fees for medical cannabis establishments may not exceed five thousand dollars, with this upper limit adjusted annually for inflation; (b) The total fees collected shall generate revenues sufficient to offset all expenses of implementing and administering this chapter; (c) A sliding scale of patient application and renewal fees based upon a qualifying patient's household income; (d) The fees charged to qualifying patients, nonresident cardholders, and caregivers shall be no greater than the costs of processing the application and issuing a registry identification card or registration; and (e) The department may accept donations from private sources to reduce application and renewal fees.; and (11) Governing medical cannabis establishments concerning the isomerization of cannabinoids to create isomers of tetrahydrocannabinol, including delta-8, delta-9, and delta-10 tetrahydrocannabinol; and the sale, and distribution of hemp or hemp products that were created using the isomerization of cannabinoids to create isomers of tetrahydrocannabinol, including delta-8, delta-9, and delta-10 tetrahydrocannabinol. A violation of a required or prohibited action under any rule authorized by this section is a Class 2 misdemeanor."}], "amendments": [], "fiscal_notes": [], "action_log": [{"bill_id": 24281, "action_date": "2023-02-01T14:00:00-06:00", "document_id": 247777, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/247777.pdf", "status_text": "First read in House and referred to", "journal_page": 196, "committee_id_action": 1159, "committee_id_assigned": 1166, "result": "N", "vote": {}}, {"bill_id": 24281, "action_date": "2023-02-08T07:45:00-06:00", "document_id": 248686, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/248686.pdf", "status_text": "Scheduled for hearing", "journal_page": 1, "committee_id_action": 1166, "committee_id_assigned": null, "result": "N", "vote": {}}, {"bill_id": 24281, "action_date": "2023-02-08T07:45:00-06:00", "document_id": 248688, "document_url": "https://mylrc.sdlegislature.gov/api/Documents/248688.pdf", "status_text": "Tabled", "journal_page": null, "committee_id_action": 1166, "committee_id_assigned": null, "result": "P", "vote": {"vote_id": 76976, "president_vote": null, "Excused": [4334, 4470, 4392], "Yea": [4337, 4341, 4343, 4344, 4353, 4366, 4368, 4385, 4409, 4408]}}], "rss_feed": "https://sdlegislature.gov/api/Bills/RSS/24281"}